# A Trial of Setmelanotide in Acquired Hypothalamic Obesity

> **NCT05774756** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Hypothalamic Obesity

## Interventions

- **DRUG:** Setmelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05774756
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2025-03-18
- **Final completion:** 2027-04-16
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05774756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05774756, "A Trial of Setmelanotide in Acquired Hypothalamic Obesity". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05774756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*